BIRC5 and hepatocellular carcinoma: Thus, the aim of the current study was to assess the therapeutic efficacy of the additional transarterial injection of Survivin siRNA to the regular TACE protocol compared to the regular TACE protocol in an animal model of hepatocellular carcinoma, and its effect on tumor growth, angiogenesis and vascular endothelial growth factor expression (VEGF) levels.